Why the study?
Does high dose venlafaxine XL affect cardiovascular safety parameters in patients with major depressive disorder?
Does high dose venlafaxine XL affect cardiovascular safety parameters in patients with major depressive disorder?
High dose venlafaxine XL in patients with major depressive disorder does not significantly affect ECG parameters, though it may cause hypertension in a minority of patients.
Supports BP monitoring with high-dose venlafaxine; leaves open randomized confirmation of neutral ECG effects.
OBJECTIVE: To assess cardiovascular safety profile of high dose Venlafaxine XL in patients with major depression. METHOD: Effects of high dose venlafaxine (mean 346.15 mg;) on the cardiovascular system in 37 patients with major depressive disorder were evaluated: BP, ECG (PR, QT, QRSD and QTc intervals) and heart rate. RESULTS: 12.5% of patients developed hypertension after starting treatment with venlafaxine. There was an association between heart rate and the dose of venlafaxine although not statistically significant. There was no association between dose of venlafaxine and PR, QT, QRSD and QTc intervals. One patient on 300 mg who was hypertensive and on other medications that may prolong QTc, had mildly prolonged QTc. However this was not clinically significant. CONCLUSION: This study of subjects on high dose venlafaxine (mean 346.15 mg; range 225-525 mg) did not demonstrate any clinical or statistically significant effects on electrocardiogram (ECG) parameters including PR, QT, QRSD and QTc interval.
No takes yet. Share an insight, caveat, or question.
Mbaya et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: